Triethanolamine Salicylate has 31 known drug interactions based on U.S. FDA drug labeling data. 31 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Acetaminophen, Acetazolamide, Articaine. Patients taking Triethanolamine Salicylate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 31
- Major
- 31
Major (31)
- Triethanolamine Salicylate + Acetaminophen— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Acetazolamide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Articaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Benzocaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Bupivacaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Chloroquine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Cyclophosphamide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Dapsone— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Flutamide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Hydroxyurea— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Ifosfamide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Lidocaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Mepivacaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Metoclopramide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Nitric Oxide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Nitrofurantoin— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Nitroglycerin— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Nitroprusside— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Nitrous Oxide— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Para-Aminosalicylic Acid— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Phenobarbital— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Phenytoin— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Prilocaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Primaquine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Procaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Quinine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Rasburicase— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Ropivacaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Sulfasalazine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Tetracaine— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Triethanolamine Salicylate + Valproate Sodium— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.